IDEAYA Biosciences, Inc.
NASDAQ:IDYABiotechnology
-$0.45 today
- Market cap
- $2.56B
- Beta
- -0.05
- P/E (TTM)
- -19.5
- EPS (TTM)
- -$1.58
Volume 1.45M
Average 1.44M
IDYA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
IDEAYA Biosciences, Inc.NASDAQ: IDYA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $98.54M (cash outflow) rose 36.5% year over year, ahead of the -54.4% change in trailing-twelve-month net income. Sequentially, it rose 18.3% from the prior quarter. Over 3 fiscal years it compounded at +24.7% a year.
Context
- Net income amounted to 52.0% of revenue in FY2025, down 3869.1 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 11 analysts of -$406.98M (+258.0%) for the fiscal year ending Dec 2026, a step up from the -58.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$98.54M+18.3% QoQ
- Last fiscal yearDec 2025
- -$113.7M-58.6% YoY
- LTMMar 2026
- -$140.06M-54.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +36.5% | +40.4% | +3.8 pp |
| 1 year | -58.6% | +258.0% | +316.5 pp |
| 3-year CAGR | +24.7% | +47.1% | +22.4 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (113.7M) USD
- Year-over-year change
- +58.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (113.7M) | +58.6% |
| FY2024 | 2024-12-31 | (274.48M) | -143.0% |
| FY2023 | 2023-12-31 | (112.96M) | -92.6% |
| FY2022 | 2022-12-31 | (58.66M) | -17.9% |
| FY2021 | 2021-12-31 | (49.76M) | — |
Net Income vs competitors
How IDYA compares with its peers on the latest reported figures
- IDYA's LTM Mar 2026 net income of $140.06M is the 7th largest of the 9 companies compared; the peer median is $200.98M.
- Its year-over-year change of -54.4% is the lowest of 9, against a peer median of +69.9%.
- Net income amounts to 62.2% of revenue for IDYA, versus a peer median of 329.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.77B | +117.8% | +65.7% | — | |
| LTM Jun 2026 | $377.18M | +32.8% | +32.9% | — | |
| LTM Sep 2026 | $307.94M | +141.2% | -20.0% | — | |
| LTM Aug 2026 | $294.88M | +220.5% | +13.6% | 42.0% | |
| LTM Sep 2026 | $208M | +106.9% | -2.1% | — | |
| LTM Mar 2026 | $193.96M | +30.3% | +41.6% | 391.2% | |
| LTM Mar 2026 | $140.06M | -54.4% | +24.7% | 62.2% | |
| LTM Mar 2026 | $77.8M | -39.1% | -4.8% | 465.3% | |
| LTM Mar 2026 | $75.32M | -6.4% | -12.0% | 266.9% | |
| Peer median (excluding IDYA) | $200.98M | +69.9% | +5.8% | 329.0% | |
Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (49.76M) | (58.66M) | (112.96M) | (274.48M) | (113.7M) |
| Depreciation & Amortization | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.24M | 11.63M | 18.49M | 34.75M | 46.12M |
| Change in Working Capital | (17.81M) | (41.56M) | (13.21M) | 11.55M | 1.87M |
| Accounts Receivables | 774K | 892K | 193K | 15K | 0 |
| Inventory | 3.79M | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.17M | 1.86M | 2.64M | 8.28M | 2.7M |
| Other Working Capital | (23.54M) | (44.31M) | (16.04M) | 3.25M | (829K) |
| Other Non-Cash Items | 1.83M | (695K) | (11.55M) | (23.23M) | (9.98M) |
| Operating Cash Flow | (55.78M) | (87.18M) | (115.22M) | (247.58M) | (71.1M) |
| Capital Expenditures | (2.64M) | (3.44M) | (2.37M) | (3.86M) | (2.37M) |
| Acquisitions (Net) | 67.02M | 33.4M | 0 | 0 | 0 |
| Purchases of Investments | (315M) | (255.81M) | (595.98M) | (1.19B) | (607.89M) |
| Sales of Investments | 247.97M | 225.85M | 439.89M | 692.61M | 680.23M |
| Other Investing Activities | (67.02M) | (33.4M) | 0 | 0 | 0 |
| Investing Cash Flow | (69.67M) | (33.4M) | (158.46M) | (502.56M) | 69.98M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 143.25M | 94.96M | 309.76M | 654.23M | 29.78M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.2M | 2.2M | 10.77M | 13.92M | 0 |
| Financing Cash Flow | 145.45M | 97.17M | 362.72M | 677.55M | 29.78M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (210K) |
| Net Change in Cash | 20.01M | (23.41M) | 89.04M | (72.59M) | 28.45M |
| Free Cash Flow | (58.42M) | (90.62M) | (117.59M) | (251.44M) | (73.47M) |
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
Intrinsic Alpha fair value
Locked
Current Price
$26.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.